It ultimately raked in billions of dollars in sales for the first approved COVID-19 vaccine. Pfizer also made a fortune with ...

Chris Boshoff will take on the role of chief scientific officer starting Jan 1 & oversee all functions of research & development across all therapeutic area ...

"Dr Boshoff is the ideal leader to propel Pfizer's R&D engine forward and transform it into a world-leading organisation with ...

▎药明康德内容团队编辑今日，美国盖伦基金会（TheGalien Foundation）公布了素有“医药界的诺贝尔奖”之称的盖伦奖（PrixGalien USA ...

Pfizer said on Wednesday it has named company veteran and oncology head Chris Boshoff as its chief of research and ...

As for his soon-to-be former role, Boshoff will be succeeded by Dr. Roger Dansey, who will serve as the interim chief ...

Pfizer's stock appears undervalued with a high dividend yield of 6.8%, making it a potential long-term investment despite low growth expectations. The company reported strong Q3 results with 31.2% YoY ...

A boost from COVID-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher forecast for the year.

A boost from COVID-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher forecast for the year. Demand for the drugmaker’s Paxlovid treatment spurred by the ...

Demand for the drugmaker’s Paxlovid treatment spurred by the latest COVID wave and a US national stockpile delivery led to US$2.7 billion in sales for the drug, Pfizer said Tuesday (Oct 29).

Pfizer said on Wednesday it has named company veteran Chris Boshoff, who led the drugmaker's cancer research and marketing ...